集成式优化发展环境 推动生物医药产业全链开放创新

Core Viewpoint - The approval of the "Biopharmaceutical Industry Chain Open Innovation Development Plan" by the State Council provides opportunities for Jiangsu Province to strengthen and expand its leading position in the biopharmaceutical industry during the 14th Five-Year Plan period [1] Group 1: Policy Recommendations - Strengthen integrated policy supply and enhance service effectiveness by implementing an "Excellence Cultivation Plan" for innovative pharmaceutical companies and optimizing clinical trial subsidy application processes [1] - Promote an "early intervention, rolling submission" approval pathway for innovative drugs and medical devices, and establish a "one product, one special class" service mechanism [1] - Establish a "white list" system for the import and export of research and development materials in biopharmaceuticals and streamline the approval process for drug marketing licenses and production licenses [1] Group 2: Innovation Ecosystem - Build a comprehensive innovation ecosystem to enhance core industry momentum by attracting national clinical medical research centers and major infrastructure projects to Jiangsu [1] - Accelerate the establishment of provincial smart pharmacy laboratories and leverage national university technology transfer centers to support the establishment of new R&D institutions [1] - Implement a green channel for the listing and coding of innovative medical devices and promote data governance across departments in healthcare [1] Group 3: Talent and Financial Support - Strengthen support for essential resources by establishing a joint recruitment and cross-training mechanism for top talents between research institutions and enterprises [1] - Include AI pharmaceutical algorithm engineers in the provincial key talent cultivation directory and develop a supporting system for high-end talent [1] - Innovate financing products to support the development of customized financial products such as intellectual property pledge loans and establish an international drug registration service center [1]